Cargando…

Development of a Brazilian anticholinergic activity drug scale

OBJECTIVE: To develop a scale of anticholinergic activity drugs used in Brazil, to be applied in health care and pharmacoepidemiology research. METHODS: We performed a literature review on PubMed/MEDLINE(®) to identify previously published scales of anticholinergic drugs. This scale started with ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Nery, Raiany Thaimeny, Reis, Adriano Max Moreira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Israelita de Ensino e Pesquisa Albert Einstein 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443211/
https://www.ncbi.nlm.nih.gov/pubmed/30942279
http://dx.doi.org/10.31744/einstein_journal/2019AO4435
_version_ 1783407824388227072
author Nery, Raiany Thaimeny
Reis, Adriano Max Moreira
author_facet Nery, Raiany Thaimeny
Reis, Adriano Max Moreira
author_sort Nery, Raiany Thaimeny
collection PubMed
description OBJECTIVE: To develop a scale of anticholinergic activity drugs used in Brazil, to be applied in health care and pharmacoepidemiology research. METHODS: We performed a literature review on PubMed/MEDLINE(®) to identify previously published scales of anticholinergic drugs. This scale started with anticholinergic drugs, and those with known anticholinergic activity as per the 4(th) level, chemical-therapeutic subgroup, of the Anatomical Therapeutic Chemical classification. We also included drugs with high anticholinergic activity, as described in a list of potentially inappropriate medications for use in older adults, according to the 2015 American Geriatrics Society Beers Criteria. Drugs listed in at least two anticholinergic scales were added. Then we verified which drugs in the previous steps were marketed in Brazil. We assigned a score of 1, 2 and 3, based on their anticholinergic action. RESULTS: A total of 273 anticholinergic drugs were identified, of which 125 were included in the scale. We identified 45 (36.0%) drugs with a score of 3, 13 (10.4%) with a score of 2, and 67 (53.6%) with a score of 1. Drugs for the nervous and respiratory systems were the most frequent in the scale. Eight drugs were not present in previous scales. CONCLUSION: The methodology used for development of the Brazilian anticholinergic activity scale is simple, systematized, reproducible and easy to update. The scale allows evaluating the impact of anticholinergic burden on health outcomes, and can potentially contribute to pharmacoepidemiology research, leading to more accurate measurements of anticholinergic activity.
format Online
Article
Text
id pubmed-6443211
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Instituto Israelita de Ensino e Pesquisa Albert Einstein
record_format MEDLINE/PubMed
spelling pubmed-64432112019-04-05 Development of a Brazilian anticholinergic activity drug scale Nery, Raiany Thaimeny Reis, Adriano Max Moreira Einstein (Sao Paulo) Original Article OBJECTIVE: To develop a scale of anticholinergic activity drugs used in Brazil, to be applied in health care and pharmacoepidemiology research. METHODS: We performed a literature review on PubMed/MEDLINE(®) to identify previously published scales of anticholinergic drugs. This scale started with anticholinergic drugs, and those with known anticholinergic activity as per the 4(th) level, chemical-therapeutic subgroup, of the Anatomical Therapeutic Chemical classification. We also included drugs with high anticholinergic activity, as described in a list of potentially inappropriate medications for use in older adults, according to the 2015 American Geriatrics Society Beers Criteria. Drugs listed in at least two anticholinergic scales were added. Then we verified which drugs in the previous steps were marketed in Brazil. We assigned a score of 1, 2 and 3, based on their anticholinergic action. RESULTS: A total of 273 anticholinergic drugs were identified, of which 125 were included in the scale. We identified 45 (36.0%) drugs with a score of 3, 13 (10.4%) with a score of 2, and 67 (53.6%) with a score of 1. Drugs for the nervous and respiratory systems were the most frequent in the scale. Eight drugs were not present in previous scales. CONCLUSION: The methodology used for development of the Brazilian anticholinergic activity scale is simple, systematized, reproducible and easy to update. The scale allows evaluating the impact of anticholinergic burden on health outcomes, and can potentially contribute to pharmacoepidemiology research, leading to more accurate measurements of anticholinergic activity. Instituto Israelita de Ensino e Pesquisa Albert Einstein 2019-03-18 /pmc/articles/PMC6443211/ /pubmed/30942279 http://dx.doi.org/10.31744/einstein_journal/2019AO4435 Text en https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Nery, Raiany Thaimeny
Reis, Adriano Max Moreira
Development of a Brazilian anticholinergic activity drug scale
title Development of a Brazilian anticholinergic activity drug scale
title_full Development of a Brazilian anticholinergic activity drug scale
title_fullStr Development of a Brazilian anticholinergic activity drug scale
title_full_unstemmed Development of a Brazilian anticholinergic activity drug scale
title_short Development of a Brazilian anticholinergic activity drug scale
title_sort development of a brazilian anticholinergic activity drug scale
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6443211/
https://www.ncbi.nlm.nih.gov/pubmed/30942279
http://dx.doi.org/10.31744/einstein_journal/2019AO4435
work_keys_str_mv AT neryraianythaimeny developmentofabraziliananticholinergicactivitydrugscale
AT reisadrianomaxmoreira developmentofabraziliananticholinergicactivitydrugscale